Table 1 Clinically significant upper and lower GI events: primary analysis
From: GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded end point (PROBE) trial
| Â | Â | Celecoxib | nsNSAID | ||
|---|---|---|---|---|---|
| Â | Â | N | Patients With Event n (%) | N | Patients With Event n (%) |
All patients | 4035 | 54 (1.3) | 4032 | 98 (2.4) | |
H pylori status | Positive | 1401 | 25 (1.8) | 1386 | 34 (2.5) |
| Â | Negative | 2634 | 29 (1.1) | 2646 | 64 (2.4) |
OR (95% CI); P value | 1.82 (1.31-2.55); p = 0.0003 | ||||